Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model

• Published in: Neuropharmacology Vol. 218; p. 109213
• Main Authors: Eteläinen, Tony S., Kilpeläinen, Tommi P., Ignatius, Adele, Auno, Samuli, De Lorenzo, Francesca, Uhari-Väänänen, Johanna K., Julku, Ulrika H., Myöhänen, Timo T.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.11.2022
• Subjects: A53T-α-synuclein; Neurodegeneration; Oligomers; Parkinson's disease; Prolyl oligopeptidase; Oligomers; Parkinson's disease; A53T-α-synuclein; PD; Neurodegeneration; Prolyl oligopeptidase; PREP; αSyn
• DOI: 10.1016/j.neuropharm.2022.109213
• ISSN: 0028-3908

Parkinson's disease (PD) is characterized by degeneration of nigrostriatal dopaminergic neurons and accumulation of α-synuclein (αSyn) as Lewy bodies. Currently, there is no disease-modifying therapy available for PD. We have shown that a small molecular inhibitor for prolyl oligopeptidase (PREP), KYP-2047, relieves αSyn-induced toxicity in various PD models by inducing autophagy and preventing αSyn aggregation. In this study, we wanted to study the effects of PREP inhibition on different αSyn species by using cell culture and in vivo models. We used Neuro2A cells with transient αSyn overexpression and oxidative stress or proteasomal inhibition-induced αSyn aggregation to assess the effect of KYP-2047 on soluble αSyn oligomers and on cell viability. Here, the levels of soluble αSyn were measured by using ELISA, and the impact of KYP-2047 was compared to anle138b, nilotinib and deferiprone. To evaluate the effect of KYP-2047 on αSyn fibrillization in vivo, we used unilateral nigral AAV1/2-A53T-αSyn mouse model, where the KYP-2047 treatment was initiated two- or four-weeks post injection. KYP-2047 and anle138b protected cells from αSyn toxicity but interestingly, KYP-2047 did not reduce soluble αSyn oligomers. In AAV-A53T-αSyn mouse model, KYP-2047 reduced significantly proteinase K-resistant αSyn oligomers and oxidative damage related to αSyn aggregation. However, the KYP-2047 treatment that was initiated at the time of symptom onset, failed to protect the nigrostriatal dopaminergic neurons. Our results emphasize the importance of whole αSyn aggregation process in the pathology of PD and raise an important question about the forms of αSyn that are reasonable targets for PD drug therapy. [Display omitted] •A cytosolic serine protease, PREP, is associated with neurodegeneration.•PREP inhibition has demonstrated protective effects in αSyn-based PD models.•PREP inhibition improved cell viability without reducing soluble αSyn oligomers.•PREP inhibition reduced insoluble αSyn oligomers and oxidative damage in vivo.•However, treatment initiated at the symptom-onset did not protect TH+ neurons.